The Patent Finder

Terms ending in 2039

Immunocore Limited

Every in-force patent on Immunocore Limited's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 11,639,374T Cell Receptors Specific for the NY-ESO-1 Tumor ANTIGEN-HLA-A*02 Complex
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 11,440,944Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 12,606,607T Cell Receptors
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 11,827,688Dosing Regimen for GP100-Specific TCR - ANTI-CD3 SCFV Fusion Protein
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited